Drug-resistant tuberculosis medical therapy: Difference between revisions
(/* Extensively Drug-Resistant XDR Tuberculosis Adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed. {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines...) |
(/* Multiple Drug-Resistant (MDR) Tuberculosis Adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed. {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines ...) |
||
Line 75: | Line 75: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1: First-line oral drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1: First-line oral drugs</u>''' <br> | ||
▸ ''' [[Pyrazinamide]]''' <br> OR <br> ▸ '''[[Ethambutol]] ''' <br> OR <br> ▸ '''[[Rifabutin]]''' | ▸ ''' [[Pyrazinamide]] 20-30 mg/kg (Max: 600 mg)''' <br> OR <br> ▸ '''[[Ethambutol]] 15-20 mg/kg''' <br> OR <br> ▸ '''[[Rifabutin]]''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2: Injectable drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2: Injectable drugs</u>''' <br> | ||
▸ '''[[Capreomycin]]'''<br> OR <br> ▸ '''[[Kanamycin]]'''<br> OR <br> ▸ '''[[Amikacin]]'''<br> OR <br> ▸ '''[[Streptomycin]]''' | ▸ '''[[Capreomycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Kanamycin]] 15-30 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Amikacin]] 15-22.5 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Streptomycin]] 12-18 mg/kg''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3: Fluoroquinolones</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3: Fluoroquinolones</u>''' <br> | ||
▸ '''[[Levofloxacin]]'''<br> OR <br> ▸ '''[[Moxifloxacin]]'''<br> OR <br> ▸ '''[[Ofloxacin]]''' | ▸ '''[[Levofloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Moxifloxacin]] 7.5-10 mg/kg'''<br> OR <br> ▸ '''[[Ofloxacin]] 15-20 mg/kg (Max:800 mg)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | ||
▸ '''[[Ethionamide]]'''<br> OR <br> ▸ '''[[Protionamide]]''' <br> OR <br> ▸ '''[[Cycloserine]]'''<br> OR <br> ▸ '''[[Terizidone]]'''<br> OR <br> ▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]]''' | ▸ '''[[Ethionamide]] 15-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Protionamide]] 15-20 mg/kg (Max: 1000 mg)''' <br> OR <br> ▸ '''[[Cycloserine]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Terizidone]] 10-20 mg/kg (Max: 1000 mg)'''<br> OR <br> ▸ '''[[Aminosalicylic acid|Para-aminosalicylic acid]] 150 mg/kg (Max: 12 000 mg)''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref></small> | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5;" align=left |<small>Table adapted from WHO 2013 Treatment of tuberculosis: guidelines – 4th ed.<ref name="WHO 2013"> {{cite web| url=http://www.who.int/tb/publications/tb_treatmentguidelines/en/| title=2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition) }}</ref></small> |
Revision as of 20:29, 17 September 2014
Tuberculosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Drug-resistant tuberculosis medical therapy On the Web |
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy |
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Drug-resistant tuberculosis is caused by M. tuberculosis organisms that are resistant to at least one first-line anti-TB drug. Multidrug-resistant TB (MDR TB) is resistant to more than one anti-TB drug and at least isoniazid (INH) and rifampin (RIF). Treatment should be started with an empirical treatment of at least 4 drugs based on expert advice as soon as drug-resistant TB disease is suspected.
Multiple Drug-Resistant (MDR) Tuberculosis Adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed. [1]
- MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
- Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR. Within these 4 drugs must be included at least one drug from each group.
- Treatment duration will depend on the culture results. The duration of therapy should be > 18 months after culture is negative.
- Chronic cases with severe pulmonary disease may require more than 24 months of therapy.
- Drugs in each group must be used, in order of preference, as shown below.[2]
- The following treatment regimens show daily dosing for each drug.
▸ Click on the following categories to expand treatment regimens.
MDR Tuberculosis ▸ Adults ▸ Children |
|
Extensively Drug-Resistant XDR Tuberculosis Adapted from WHO 2013 Treatment of Tuberculosis: Guidelines – 4th ed. [1]
- XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone (Group 3), and to any of the three second-line injectables (Group 4: amikacin, capreomycin, and kanamycin).
- Additional drugs are needed for XDR treatment regimen, these drugs are known to have some action against tuberculosis but are not routinely recommended for treatment of MDR-TB.
- These include clofazimine, linezolid, amoxicillin/clavulanate, thioacetazone, imipenem/cilastatin, clarithromycin and high-dose isoniazid.
- The treatment regimen should include from 4 to 6 drugs, based on the suceptibility of the M. tuberculosis and the clinician criteria.
- Treatment duration is not well established, but is longer than MDR-TB. For some cases, at least 43 months are required for XDR-TB treatment to be successful.[3]
- The following treatment regimens show daily dosing for each drug.
▸ Click on the following categories to expand treatment regimens.
XDR Tuberculosis ▸ Adults ▸ Children |
|
Extremely Drug-Resistant (XXDR) Tuberculosis
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "2013 WHO Treatment of Tuberculosis: Guidelines for National Programmes (4th Edition)".
- ↑ Caminero, José A; Sotgiu, Giovanni; Zumla, Alimuddin; Migliori, Giovanni Battista (2010). "Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis". The Lancet Infectious Diseases. 10 (9): 621–629. doi:10.1016/S1473-3099(10)70139-0. ISSN 1473-3099.
- ↑ Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C; et al. (2008). "Management of extensively drug-resistant tuberculosis in Peru: cure is possible". PLoS One. 3 (8): e2957. doi:10.1371/journal.pone.0002957. PMC 2495032. PMID 18698423.